JP2021514975A5 - - Google Patents
Info
- Publication number
- JP2021514975A5 JP2021514975A5 JP2020544823A JP2020544823A JP2021514975A5 JP 2021514975 A5 JP2021514975 A5 JP 2021514975A5 JP 2020544823 A JP2020544823 A JP 2020544823A JP 2020544823 A JP2020544823 A JP 2020544823A JP 2021514975 A5 JP2021514975 A5 JP 2021514975A5
- Authority
- JP
- Japan
- Prior art keywords
- inhibitor
- pharmaceutically acceptable
- combination
- acceptable salt
- bromodomain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862635916P | 2018-02-27 | 2018-02-27 | |
| US62/635,916 | 2018-02-27 | ||
| US201962796223P | 2019-01-24 | 2019-01-24 | |
| US62/796,223 | 2019-01-24 | ||
| PCT/IB2019/051462 WO2019166928A1 (en) | 2018-02-27 | 2019-02-22 | Combination of a cyclin dependent kinase inhibitor and a bet-bromodomain inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021514975A JP2021514975A (ja) | 2021-06-17 |
| JP2021514975A5 true JP2021514975A5 (enExample) | 2022-03-02 |
Family
ID=65904498
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020544823A Pending JP2021514975A (ja) | 2018-02-27 | 2019-02-22 | サイクリン依存性キナーゼ阻害剤およびｂｅｔ−ブロモドメイン阻害剤の組合せ |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20200405809A1 (enExample) |
| EP (1) | EP3758753A1 (enExample) |
| JP (1) | JP2021514975A (enExample) |
| CA (1) | CA3092003A1 (enExample) |
| WO (1) | WO2019166928A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI841598B (zh) * | 2018-09-13 | 2024-05-11 | 大陸商恒翼生物醫藥（上海）股份有限公司 | 用於治療雌激素受體陽性乳癌之組合療法 |
| CN114502534A (zh) * | 2019-09-30 | 2022-05-13 | 协和麒麟株式会社 | Bet降解剂 |
| JP2023509191A (ja) * | 2020-01-09 | 2023-03-07 | アストラゼネカ・アクチエボラーグ | 癌を治療するための組み合わせ療法 |
| JP7579564B2 (ja) | 2020-10-28 | 2024-11-08 | 国立大学法人金沢大学 | Ｒｂ１陽性癌の治療用医薬組成物及びキット |
| CA3251059A1 (en) | 2022-05-02 | 2023-11-09 | The Board Of Trustees Of The Leland Stanford Junior University | Compositions, systems and methods for modulating a target gene |
| CN117100868A (zh) * | 2023-10-10 | 2023-11-24 | 复旦大学 | 溶瘤单纯疱疹病毒oHSV联合NETosis抑制剂在制备抗肿瘤药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
| WO2000035298A1 (en) | 1996-11-27 | 2000-06-22 | Wm. Wrigley Jr. Company | Chewing gum containing medicament active agents |
| NZ534069A (en) | 2002-01-22 | 2007-03-30 | Warner Lambert Co | 2-(Pyridin-2-ylamino)-pyrido[2,3-d]pyrimidin-7-ones to be used to treat neurodegenerative disorders, viruses and cancer |
| DE602004017474D1 (de) | 2003-07-11 | 2008-12-11 | Warner Lambert Co | Isethionat salz eines selektiven cdk4 inhibitors |
| KR20090052385A (ko) | 2006-09-08 | 2009-05-25 | 화이자 프로덕츠 인크. | 2-（피리딘-2-일아미노）-피리도［2,3-ｄ］피리미딘-7-온의합성 |
| US9073878B2 (en) * | 2012-11-21 | 2015-07-07 | Zenith Epigenetics Corp. | Cyclic amines as bromodomain inhibitors |
| DK3431475T3 (da) | 2013-02-21 | 2021-05-25 | Pfizer | Faste former af en selektiv CDK4/6-hæmmer |
| US11446309B2 (en) * | 2013-11-08 | 2022-09-20 | Dana-Farber Cancer Institute, Inc. | Combination therapy for cancer using bromodomain and extra-terminal (BET) protein inhibitors |
| MX385762B (es) * | 2014-11-07 | 2025-03-18 | Sumitomo Pharma Oncology Inc | Métodos para el control transcripcional objetivo en regiones del super mejorador. |
| MX376083B (es) | 2015-06-04 | 2025-03-07 | Pfizer | Formas de dosificacion solidas de palbociclib. |
-
2019
- 2019-02-22 EP EP19713199.8A patent/EP3758753A1/en not_active Withdrawn
- 2019-02-22 WO PCT/IB2019/051462 patent/WO2019166928A1/en not_active Ceased
- 2019-02-22 US US16/975,837 patent/US20200405809A1/en not_active Abandoned
- 2019-02-22 CA CA3092003A patent/CA3092003A1/en not_active Abandoned
- 2019-02-22 JP JP2020544823A patent/JP2021514975A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20060307L (no) | Anvendelse av kinoazolinderivatet ZD6474 kombinert med platinaforbindelser og eventuelt ioniserende straling i behandling av sykdommer assosoiert med angiogenese og/eller okt vaskulaert permeabilitet | |
| Chakrabarti et al. | Synergistic anti-tumor actions of luteolin and silibinin prevented cell migration and invasion and induced apoptosis in glioblastoma SNB19 cells and glioblastoma stem cells | |
| JP2006500346A5 (enExample) | ||
| MX2021002886A (es) | Terapia de combinacion para el tratamiento de cancer de mama triple negativo. | |
| WO2009008992A3 (en) | Combination anti-cancer therapy comprising an inhibitor of both mtorc1 and mt0rc2 | |
| NO20066056L (no) | Behandling med Gemcitabin og en EGFR-inhibitor | |
| NO20014842L (no) | Docetaksel i kombinasjon med rhuMAb HER2 for behandling av kreft | |
| WO2007106503A3 (en) | Combined treatment with an egfr kinase inhibitor and an agent that sensitizes tumor cells to the effects of egfr kinase inhibitors | |
| BR0115109A (pt) | Agentes terapêuticos e métodos de uso dos mesmos para a modulação da angiogênese | |
| DK1551409T3 (da) | Anvendelse af quinazolinderivatet ZD6474 kombineret med gemcitabin og eventuelt ioniserende stråling ved behandling af cancer | |
| CA2972699A1 (en) | Synchronizing tumor cells to the g2/m phase using ttfields combined with taxane or other anti-microtubule agents | |
| BRPI0408005A (pt) | composto, composição farmacêutica, métodos para inibir angiogênese, atividade de pde4 em uma célula e proliferação de célula de cáncer, para inibir ou reduzir polimerização de tubulina ou estabilidade de tubulina em uma célula, para tratar ou melhorar um distúrbio inflamatório, um cáncer e um distúrbio do sistema nervoso central e para visar, bloquear ou destruir a função de vasculatura de tumor e o endotélio de vasos de tumor | |
| NO20071426L (no) | Kreft kombinasjonsbehandling omfattende AZD2171 og Imatinib | |
| NO20050528L (no) | Kombinasjon av VEGF reseptor tyrosin kinase inhibitorer for behandling av kreft | |
| JP2023533464A5 (enExample) | ||
| TW200626159A (en) | Therapeutic combinations comprising poly (ADP-ribose) polymerases inhibitor | |
| TW200744636A (en) | Combined treatment with and composition of 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitor and anti-cancer agents | |
| IS2114B (is) | Kínasólínafleiður til að meðhöndla æxli | |
| NO20071428L (no) | Kombinasjon inneholdende ZD6474 og Imatinib | |
| BR0314797A (pt) | Derivados da pirimidineamida e o uso dos mesmos | |
| JP2017533222A5 (enExample) | ||
| NO20055891L (no) | Kinazolinderivater som aurorakinaseinhibitorer | |
| WO2006110175A3 (en) | Combined treatment with bortezomib and an epidermal growth factor receptor kinase inhibitor | |
| BRPI0510657A (pt) | tratamento com cisplatina e com um inibidor de egfr | |
| Anai et al. | Antitumor effect of fibrin glue containing temozolomide against malignant glioma |